ODAC Briefing Document NDA[removed]

First Page		Document Content
Carfilzomib Epoxides Morpholines Immunosuppressants Bortezomib Lenalidomide Onyx Pharmaceuticals Proteasome inhibitor Multiple myeloma Medicine Chemistry Organic chemistry		ODAC Briefing Document NDA[removed] Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 833,49 KB Share Document on Facebook

	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVLIMID® safely and effectively. See full prescribing information for REVLIMID. REVLIMID [lenalidomide] capsules, DocID: 1tonS - View Document
	Revlimid, INN-lenalidomide DocID: 1szTz - View Document
	Pipette, Seite 11–13 Monoklonale Gammopathien: Neue IMWG-Kriterien und Labortests für die Diagnose, Prognose und Verlaufskontrolle des Multiplen Myeloms Luca Bernasconi, Esther Mundwiler Referenzen 1. DocID: 1rfhH - View Document
	12-AUG:10 MMYEL ACCRUAL REPORT - Open and Recently Closed Studies SWOG/ Support STUDY DocID: 1qMvA - View Document
	PUBLICATION DU GINECO Année 2014 Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A,.Lortholary A, PujadeLauraine E. A phase II study of lenalidomide in platinum-sensitive recurrent DocID: 1qvQ0 - View Document